Ozmosi | BLB-301 Drug Profile
Drug Profile
Using advanced filters...
Advanced Search [+]

BLB-301

Alternative Names: BLB-301, BLB301, BLB 301
Clinical Status: Active
Latest Update: 2025-10-01
Latest Update Note: Clinical Trial Update

Product Description

(Sourced from: https://www.baylinkbio.com/pipeline)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Baylink Bio
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 0: Oncology Solid Tumor Unspecified

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title